论文部分内容阅读
目的:探讨鳞状细胞癌相关抗原(SCCA)检测在不同临床分期宫颈磷癌治疗前后变化。方法:收集我院2013年4月—2013年12月收治的95例宫颈磷癌患者(观察组)和同期60例健康女性(对照组)血清样本,用新产业全自动化学发光免疫分析仪测定SCCA水平值。结果:观察组血清SCCA阳性率明显高于对照组,差异有统计学意义(P<0.01);宫颈癌Ⅳ期SCCA浓度值和阳性率明显高于宫颈癌Ⅰ期~Ⅲ期,差异有统计学意义(P<0.01);宫颈癌治疗后SCCA浓度值明显低于治疗前SCCA值,差异有统计学意义(P<0.01)。结论:SCCA是诊断宫颈癌特异性较强的标志物,根据不同临床分期宫颈癌患者血清SCCA水平差异及治疗后的变化,为临床辅助诊断宫颈癌及预后价值提供参考。
Objective: To investigate the changes of squamous cell carcinoma-associated antigen (SCCA) before and after treatment of cervical cancer with different clinical stages. Methods: Serum samples from 95 patients with cervical cancer of the cervix (observation group) and 60 healthy women (control group) who were treated in our hospital from April 2013 to December 2013 were collected and analyzed by a new industrial automated chemiluminescence immunoassay SCCA level. Results: The positive rate of SCCA in observation group was significantly higher than that in control group (P <0.01). The SCCA concentration and positive rate in stage Ⅳ cervical cancer were significantly higher than those in stage Ⅰ ~ Ⅲ cervical cancer, the difference was statistically significant (P <0.01). The SCCA concentration of cervical cancer after treatment was significantly lower than that before treatment, the difference was statistically significant (P <0.01). Conclusion: SCCA is a specific marker for diagnosing cervical cancer. Based on the difference of serum SCCA level and changes after treatment, SCCA may provide reference for clinical diagnosis of cervical cancer and prognosis.